Sustaining remission in rheumatoid arthritis: the role of clinical deep remission and its implications for drug tapering
Authors' conclusion
Our findings suggest that achieving CliDR is associated with significantly higher sustained remission rates in RA and that the safety of treatment tapering is contingent on prior achievement of CliDR.
Study context
- Population
- Patients with rheumatoid arthritis (RA) who achieved DAS28-CRP remission with 5 years of follow-up after remissionof 541 enrolled
- Participants
- 145 patients
- Exposure
- Clinical deep remission (CliDR) vs non-CliDR
- Outcome
- Sustained remission rate
- Follow-up
- 5 years
Methodological detailsreal-world, Kaplan-Meier analysis, multivariable Cox regression with time-dependent covariates
- Real-world
- Kaplan-Meier analysis
- Multivariable Cox regression with time-dependent covariates
Main finding
As reported in the abstract
P = 0.014
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Relapse with tapering in non-CliDR (subgroup)Taperingvs No taperingnon-CliDR group | 8.47 (5.01–14.32) | P < 0.001 | |
| Interaction between group and tapering on relapseInteraction term; effect of tapering attenuated in CliDR | 0.26 (0.07–0.98) | P = 0.046 | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Sustaining remission in rheumatoid arthritis: the role of clinical deep remission and its implications for drug tapering. RMD Open. Published 24 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →